Glenmark receives USFDA approval for generic version of Taytulla?1 Capsules

29 Jul 2022 , 09:13 AM

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (U.S. FDA) for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules, 1 mg/20 mcg, the generic version of Taytulla?1 Capsules, of Allergan Pharmaceuticals International. According to IQVIATM sales data for the 12 month period ending May 2022, the Taytulla? Capsules market achieved annual sales of approximately $85.9 million. Powered by Capital Market – Live News